MedTrace Logo

Liposomal vs. Conventional Bupivacaine for Pain Control

NCT06231355 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2025-07-30

No results posted yet for this study

Summary

The goal of this pilot study is to test the hypothesis that liposomal bupivacaine extends the duration of paravertebral block in patients undergoing radical nephrectomy, achieving improved analgesia compared to conventional bupivacaine. The main questions it aims to answer are:

* Area under curve of numeric rating scale of pain from 12 to 72 h after surgery.
* Cumulative opioid consumption during the period of 12 to 72 h after surgery.

Conditions

  • Local Anesthetics
  • Analgesia
  • Regional Block
  • Paravertebral Block

Interventions

DRUG

Performing paravertebral nerve block with lipo-bupivacaine

Paravertebral block is performed using liposomal bupivacaine.

DRUG

Performing paravertebral nerve block with bupivacaine

Paravertebral block is performed using bupivacaine.

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Dong-Xin Wang, MD, PhD · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-21
Primary Completion
2024-09-09
Completion
2024-10-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06231355 on ClinicalTrials.gov